Irinotecan in the management of patients with pancreatic cancer

Mark R. Green, Melinda Harper, Ahmad Safa, Carol A. Sherman, Chaudry M. Mushtaq, Hamid Bahadori, Frank J. Brescia, Caio M.S.P. Rocha Lima

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.

Original languageEnglish (US)
Pages (from-to)31-33
Number of pages3
JournalONCOLOGY
Volume14
Issue number12 SUPPL. 14
StatePublished - Dec 1 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Irinotecan in the management of patients with pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Green, M. R., Harper, M., Safa, A., Sherman, C. A., Mushtaq, C. M., Bahadori, H., Brescia, F. J., & Rocha Lima, C. M. S. P. (2000). Irinotecan in the management of patients with pancreatic cancer. ONCOLOGY, 14(12 SUPPL. 14), 31-33.